Audio

Community Oncology Podcast - Cetuximab and FOLFIRI in colon cancer


 

Cetuximab plus FOLFIRI as a first-line therapy in metastatic colon cancer, skin toxicities associated with EGFR inhibitors, and treating hypertension in cancer patients are among the highlights of this month’s podcast, featuring Dr. David Henry, editor-in-chief of Community Oncology.

Recommended Reading

Long-Term Follow-Up Warranted After Gastric MALT Lymphoma Remission
MDedge Hematology and Oncology
Two Common Genetic Variants Linked to Barrett's Esophagus
MDedge Hematology and Oncology
FDA Approves Regorafenib for Metastatic Colorectal Cancer
MDedge Hematology and Oncology
Gefitinib Offers Palliative Care in Advanced Esophageal Cancer
MDedge Hematology and Oncology
Cetuximab Fails First-Line in Gastric Cancer
MDedge Hematology and Oncology
Screening All Colorectal Tumors Detects Lynch Syndrome Best
MDedge Hematology and Oncology
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
MDedge Hematology and Oncology
Less Liver Cancer in HCV Patients Given Antiviral Therapy
MDedge Hematology and Oncology
Immunomodulator MGN1703 Cuts Risk of Colorectal Cancer Progressing
MDedge Hematology and Oncology
Cetuximab plus FOLFIRI in first-line treatment of KRAS mutation-negative, EGFR-positive metastatic colorectal cancer
MDedge Hematology and Oncology